Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib.

Authors :: Woyach, Jennifer A.
Furman, Richard R.
Ta-Ming Liu
Ozer, Hatice Gulcin
Zapatka, Marc
Ruppert, Amy S.
Ling Xue
Hsieh-Hsin Li, Daniel
Steggerda, Susanne M.
Versele, Matthias
Dave, Sandeep S.
Zhang, Jenny
Yilmaz, Ayse Selen
Jaglowski, Samantha M.
Blum, Kristie A.
Lozanski, Arietta
Lozanski, Gerard
James, Danelle F.
Barrientos, Jacqueline C.
Lichter, Peter
Source :: New England Journal of Medicine. 6/12/2014, Vol. 370 Issue 24, p2286-2294. 9p.
Publication Year :: 2014
Abstract: The article presents a study on the resistance to ibrutinib which is an irreversible inhibitor of Bruton's tyrosine kinase (BTK). Topics include its effectiveness on the treatment of chronic lymphocytic leukemia (CLL), the use of whole-exome sequencing at baseline, and the mutation of cysteine-to-serine in BTK. It also features a table of the characteristics of patients with ibrutinib resistance.